Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 5,585 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 5,585 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.49, for a total value of $19,491.65. Following the completion of the transaction, the chief executive officer now owns 3,039,194 shares in the company, valued at $10,606,787.06. This represents a 0.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Organogenesis Trading Up 4.4 %

NASDAQ ORGO traded up $0.15 on Monday, reaching $3.55. The company had a trading volume of 390,288 shares, compared to its average volume of 841,201. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70. The stock has a market cap of $470.66 million, a price-to-earnings ratio of -59.17 and a beta of 1.73. The stock’s 50 day moving average is $3.43 and its 200-day moving average is $3.00.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period last year, the company posted $0.02 EPS. Equities analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in shares of Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after buying an additional 72,696 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Organogenesis by 76.9% in the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after acquiring an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Organogenesis by 19.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after acquiring an additional 333,123 shares in the last quarter. State Street Corp raised its position in shares of Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after purchasing an additional 23,675 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.